Publication details

<< back
 

WEDELOLACTONE REDUCES GROWTH AND INDUCES DIFFERENTIATION AND APOPTOSIS OF BREAST CANCER CELLS

Basic information
Original title:WEDELOLACTONE REDUCES GROWTH AND INDUCES DIFFERENTIATION AND APOPTOSIS OF BREAST CANCER CELLS
Authors:Petr Beneš, Diana Pinheiro, Alice Nemajerová, Lucia Knopfová, Jan Šmarda
Further information
Citation:BENEŠ, Petr - PINHEIRO, Diana - NEMAJEROVÁ, Alice - KNOPFOVÁ, Lucia - ŠMARDA, Jan. WEDELOLACTONE REDUCES GROWTH AND INDUCES DIFFERENTIATION AND APOPTOSIS OF BREAST CANCER CELLS. In Natural compounds in cancer prevention and treatment: Book of abstract. neuveden : Cancer Research Institute, Slovak Academy of Sciences and Slovak Cancer Research Foundation, 2009. ISBN 978-80-970128-2-3, p. 46-46. 2009, Smolenice.
Original language:English
Field:Oncology and hematology
Type:Article in Proceedings
Keywords:wedelolactone; breast cancer cells; growth; differentiation; apoptosis

Wedelolactone, the naturally occurring coumestan derived from Eclipta prostrate and Wedelia calendulacea, is commonly used in South American medicine as snake antivenom. In traditional Chinese medicine, coumestans are used to treat septic shock, liver diseases and viral infections. Moreover, coumestans reduce cancer risk, potentially due to their structural similarity to phytoestrogens. Recently, it was shown that wedelolactone inhibits growth of prostate and pituitary cancer cells. In this study we tested the effect of wedelolactone on breast cancer cell line MDA-MB-231. We found that 10 and 20 uM wedelolactone inhibits growth of MDA-MB-231 cells by blocking cell cycle progression in the S-phase. Growth inhibitory effect of wedelolactone was associated with cell differentiation as indicated by changes in cell morphology, accumulation of lipid droplets and over-expression of milk fat globule-EGF factor 8. The addition of 30 and 50 uM wedelolactone reduces viability and induces apoptosis of MDA-MB-231 cells documented by chromatin condensation, nuclear fragmentation and poly (ADP ribose) polymerase cleavage. We conclude that wedelolactone possess strong anti-cancer properties and could be considered as potential drug in therapy of breast cancer.

Related projects:

 
 
top